HK1207366A1 - 作為 抑制劑的塞二唑啉酮二酮 - Google Patents

作為 抑制劑的塞二唑啉酮二酮

Info

Publication number
HK1207366A1
HK1207366A1 HK15107867.8A HK15107867A HK1207366A1 HK 1207366 A1 HK1207366 A1 HK 1207366A1 HK 15107867 A HK15107867 A HK 15107867A HK 1207366 A1 HK1207366 A1 HK 1207366A1
Authority
HK
Hong Kong
Prior art keywords
gsk
thiadiazolidinediones
inhibitors
inhibitors gsk
Prior art date
Application number
HK15107867.8A
Other languages
English (en)
Inventor
Padilla Miguel Medina
Correa Juan Manuel Domnguez
Cristobal Blanco Javier De
Huerta Ana Fuertes
Jorge Snchez-Quesada
Ogalla Javier Lpez
Santos Susana Herrero
De La Cruz Moreno Mara Ngeles Prez
Montero Olga Martnez
Salguero Beatriz Rodrguez
Nicolau Francisco Palomo
Original Assignee
Asd Therapeutics Partners Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asd Therapeutics Partners Llc filed Critical Asd Therapeutics Partners Llc
Publication of HK1207366A1 publication Critical patent/HK1207366A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/081,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK15107867.8A 2012-02-24 2015-08-14 作為 抑制劑的塞二唑啉酮二酮 HK1207366A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12382066 2012-02-24
PCT/EP2013/053554 WO2013124413A1 (en) 2012-02-24 2013-02-22 Thiadiazolidinediones as gsk-3 inhibitors

Publications (1)

Publication Number Publication Date
HK1207366A1 true HK1207366A1 (zh) 2016-01-29

Family

ID=47747639

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15107867.8A HK1207366A1 (zh) 2012-02-24 2015-08-14 作為 抑制劑的塞二唑啉酮二酮

Country Status (19)

Country Link
US (2) US9371299B2 (zh)
EP (1) EP2838888B1 (zh)
JP (2) JP6073377B2 (zh)
AU (2) AU2013224041B2 (zh)
CA (1) CA2865351C (zh)
CY (1) CY1119231T1 (zh)
DK (1) DK2838888T3 (zh)
ES (1) ES2632428T3 (zh)
HK (1) HK1207366A1 (zh)
HR (1) HRP20170964T1 (zh)
HU (1) HUE035089T2 (zh)
IN (1) IN2014DN07885A (zh)
LT (1) LT2838888T (zh)
NZ (1) NZ630615A (zh)
PL (1) PL2838888T3 (zh)
PT (1) PT2838888T (zh)
SI (1) SI2838888T1 (zh)
WO (1) WO2013124413A1 (zh)
ZA (1) ZA201406225B (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2838888T3 (en) 2012-02-24 2017-07-17 Asd Therapeutics Partners Llc THIADIAZOLIDINEDIONS AS GSK-3 INHIBITORS
NZ713219A (en) 2013-03-14 2017-04-28 Massachusetts Inst Technology Compositions and methods for epithelial stem cell expansion and culture
JP6663863B2 (ja) * 2014-06-12 2020-03-13 シーダーズ−サイナイ メディカル センター がん治療のための組成物及び方法
KR102493376B1 (ko) 2014-09-03 2023-01-27 더 브리검 앤드 우먼즈 하스피털, 인크. 청력 손실의 치료를 위해 내이 털세포를 생성하기 위한 조성물, 시스템, 및 방법
CN108779437A (zh) 2016-01-08 2018-11-09 麻省理工学院 分化的肠内分泌细胞和胰岛素产生细胞的制备
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US11066419B2 (en) 2016-12-30 2021-07-20 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using same
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
AU2019321641A1 (en) 2018-08-17 2021-04-15 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating Jag-1
BR112021007208A2 (pt) * 2018-10-16 2021-08-10 Italia Technology Alliance S.R.L. máquina de enrolamento com um sistema de avaliação do material de manta sendo processado e método
AU2020218366A1 (en) 2019-02-08 2021-09-16 Frequency Therapeutics, Inc. Valproic acid compounds and Wnt agonists for treating ear disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2166328B1 (es) * 2000-05-11 2003-09-16 Consejo Superior Investigacion Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos
HUP0302002A3 (en) 2000-05-11 2007-02-28 Consejo Superior Investigacion Heterocyclic inhibitors of glycogen synthase kinase gsk-3, their use and pharmaceutical compositions containing them
EP1586318A1 (en) 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiadiazolidinones as GSK-3 inhibitors
KR100837785B1 (ko) * 2007-01-17 2008-06-13 한국화학연구원 1,2,4-티아다이아졸리딘-3,5-다이온 화합물을 포함하는염증관련 질환의 치료 및 예방을 위한 약제학적 조성물
DK2838888T3 (en) 2012-02-24 2017-07-17 Asd Therapeutics Partners Llc THIADIAZOLIDINEDIONS AS GSK-3 INHIBITORS

Also Published As

Publication number Publication date
ES2632428T3 (es) 2017-09-13
AU2017248556B2 (en) 2018-08-09
US20160257660A1 (en) 2016-09-08
EP2838888B1 (en) 2017-04-12
HRP20170964T1 (hr) 2017-10-06
JP6518270B2 (ja) 2019-05-22
JP2017081974A (ja) 2017-05-18
CA2865351C (en) 2019-08-20
AU2013224041A1 (en) 2014-09-25
JP6073377B2 (ja) 2017-02-01
NZ630615A (en) 2015-09-25
EP2838888A1 (en) 2015-02-25
ZA201406225B (en) 2016-05-25
IN2014DN07885A (zh) 2015-04-24
HUE035089T2 (hu) 2018-05-02
PT2838888T (pt) 2017-07-18
JP2015508092A (ja) 2015-03-16
SI2838888T1 (sl) 2017-09-29
US9371299B2 (en) 2016-06-21
LT2838888T (lt) 2017-08-10
US9469618B2 (en) 2016-10-18
DK2838888T3 (en) 2017-07-17
CA2865351A1 (en) 2013-08-29
US20150038538A1 (en) 2015-02-05
CY1119231T1 (el) 2018-02-14
WO2013124413A1 (en) 2013-08-29
AU2017248556A1 (en) 2017-11-09
PL2838888T3 (pl) 2017-12-29
AU2013224041B2 (en) 2017-08-24

Similar Documents

Publication Publication Date Title
HK1210775A1 (zh) 作為激酶抑制劑的咪唑並三嗪甲腈
HK1212348A1 (zh) 自分泌運動因子抑制劑
HK1208442A1 (zh) 作為 激酶抑制劑的取代的吡咯並嘧啶基氨基-苯並噻唑酮
HK1211921A1 (zh) 抑制劑化合物
HK1201200A1 (zh) 取代的吡咯烷- -甲酰胺
LT2920149T (lt) 3-aminocikloalkilo junginiai, kaip ror-gama-t inhibitoriai, ir jų panaudojimas
HK1200830A1 (zh) 取代的吡咯烷- -甲酰胺
HK1207366A1 (zh) 作為 抑制劑的塞二唑啉酮二酮
SG11201501173SA (en) PI3Kδ INHIBITOR
HK1206724A1 (zh) 取代的苯並噻吩並嘧啶
SG11201500973WA (en) Amino-quinolines as kinase inhibitors
HK1209422A1 (zh) 抑制劑
HK1209105A1 (zh) 抑制劑
HK1209104A1 (zh) 抑制劑
EP2934541A4 (en) NORIBOGAINE SUBSTITUTE
HK1206022A1 (zh) 取代的咪唑並噠嗪
GB201211019D0 (en) Inhibitor compounds
ZA201504305B (en) Autotaxin inhibitors
AP2015008541A0 (en) Autotaxin inhibitors
GB201216008D0 (en) Novel use of GSK-3 inhibitors